InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted): 2022-2025
Historic EPS (Weighted Average and Diluted) for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to -$0.44.
- InMed Pharmaceuticals' EPS (Weighted Average and Diluted) rose 83.76% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 52.78%. This contributed to the annual value of -$8.36 for FY2025, which is 58.49% up from last year.
- Latest data reveals that InMed Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.44 as of Q3 2025, which was down 2.33% from -$0.43 recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of -$0.14 during Q2 2023, and its lowest value of -$15.24 during Q3 2023.
- For the 3-year period, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$3.55, with its median value being -$3.15 (2024).
- As far as peak fluctuations go, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) slumped by 2,562.39% in 2024, and later soared by 88.25% in 2025.
- Quarterly analysis of 4 years shows InMed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$6.14 in 2022, then reached -$3.71 in 2023, then grew by 1.89% to -$3.64 in 2024, then spiked by 83.76% to -$0.44 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.44 for Q3 2025, versus -$0.43 for Q2 2025 and -$1.94 for Q1 2025.